Article
Do beta-tubulin mutations have a role in resistance to chemotherapy?
The Lancet. Oncology - 1 Mar 2004
Berrieman Helen K, Lind Michael J, Cawkwell Lynn
Abstract excerpt
beta-tubulin is the target of various antitubulin agents used in the treatment of cancer. After beta tubulin was shown to confer resistance to antitubulin agents in established cell lines, several studies have investigated the DNA sequence of this compound in clinical samples. However, these findings are highly controversial, since sequencing experiments showed that the original clinical observation of mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
